Psoriatic Arthritis News

Approximately 61% of patients with rheumatoid arthritis or psoriatic arthritis who use methotrexate report side effects following weekly dosing, including fatigue and nausea, according to data published in Rheumatology and Therapy.

Just 0.7% of fully vaccinated patients with inflammatory rheumatic and musculoskeletal disease experience a breakthrough COVID-19 infection, while only 4.4% demonstrate disease flare reactions, according to data.

Though sometimes complex, treat-to-target strategies for psoriatic arthritis can lead to lower symptom states, better physical functionality and less structural damage to joints, according to Philip Mease, MD, a clinical professor at the University of Washington School of Medicine and Director of rheumatology research at the Swedish Medical Center in Seattle.

Patients with rheumatoid arthritis, but not psoriatic arthritis or ulcerative colitis, are at a greater risk for severe or critical COVID-19 versus those with COVID-19 alone, according to data published in The Journal of Rheumatology.

In October, Boehringer Ingelheim’s adalimumab-adbm secured a landmark FDA approval as the first interchangeable biosimilar to AbbVie’s blockbuster drug, Humira — but, as rivals scramble for second place, will the designation be worth the price?

Dactylitis indicates a more severe disease phenotype independently linked to increased disease burden, with greater bone erosion, in early DMARD-naïve psoriatic arthritis, according to data published in the Annals of the Rheumatic Diseases.

DMARD interruptions in patients with autoimmune rheumatic diseases increased more than 80% between December 2020 and May 2021, leading to higher rates of self-reported flares, according to data published in Arthritis Care & Research.

The FDA has approved secukinumab for the treatment of active psoriatic arthritis in patients aged 2 years and older, and for active enthesitis-related arthritis in those aged 4 years and older.

Upadacitinib demonstrates comparable efficacy and safety as monotherapy or in combination with non-biologic disease-modifying antirheumatic drugs in patients with psoriatic arthritis, according to data published in Rheumatology.

The FDA has approved the seventh biosimilar to adalimumab, adalimumab-aqvh, for all eligible indications of the biologic product, the latest in an increasingly crowded biosimilar logjam set to release in 2023.